Key result
Transfemoral JenaValve implantation succeeds in pure aortic regurgitation with good 6-month hemodynamics and clinical outcomes.
Why the study?
A novel transfemoral self-expanding transcatheter heart valve design was developed to treat pure aortic regurgitation, especially in non-calcified anatomies.
Case Report (n=1)
No
Transfemoral implantation of the novel JenaValve is feasible and provides a promising treatment option for patients with primary aortic regurgitation and high surgical risk.
Single-case success in pure AR; hypothesis-generating and should not yet change practice.
Here we will describe the first case of a novel JenaValve design (JenaValve Technology, Irvine, CA, USA) using the transfemoral approach in a 78-year-old female patient with pure aortic regurgitation.The implantation was successfully performed with good haemodynamics and good clinical outcome at six-month follow-up.The technology is especially appealing in non-calcified anatomies due to the clipping mechanism which was previously utilised in the transapical design. AR aortic regurgitation LVleft ventricular NYHA New York Heart Association TAVI transcatheter aortic valve implantation
No takes yet. Share an insight, caveat, or question.
Schäfer et al. (2017) conducted a case report in Pure aortic regurgitation (n=1). JenaValve (novel transfemoral self-expanding transcatheter heart valve) was evaluated on Procedural success and clinical outcome at 6-month follow-up. Transfemoral implantation of the novel JenaValve was successfully performed in a 78-year-old woman with pure aortic regurgitation, resulting in good hemodynamics and clinical outcome at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: